BioWorld

July 19, 2007

Neurochem Gets 2nd Approvable For Kiacta; Analysts Pessimistic

Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today) Read More

Preparing For AzaSite Launch, Inspire Gets $75M Investment

Edison, Penwest Enter Deal On Orphan Neurological Disorders

Clinical Data Boost Vilazodone Work With $66M Public Offering

Orchestra Dumps HIV Program After Vaccine Candidate Fails

Appointments And Advancements

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...